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ABSTRACT
Background: Emapticap pegol (NOX-E36) is a SpiegelmerVR
that specifically binds and inhibits the pro-inflammatory che-
mokine C-C motif-ligand 2 (CCL2) (also called monocyte-
chemotactic protein 1). The objective of this exploratory study
was to evaluate the safety and tolerability as well as the renopro-
tective and anti-diabetic potential of emapticap in type 2 dia-
betic patients with albuminuria.
Methods: A randomized, double-blind, placebo-controlled
Phase IIa study was initiated in 75 albuminuric type 2 diabetics.
Emapticap at 0.5 mg/kg and placebo were administered subcu-
taneously twice weekly for 12 weeks to 50 and 25 patients,
respectively, followed by a treatment-free phase of 12 weeks.
Results: Twice weekly subcutaneous treatment with emapticap
over 3 months was generally safe and well tolerated and reduced
the urinary albumin/creatinine ratio (ACR) from baseline to
Week 12 by 29% (P < 0.05); versus placebo a non-significant
ACR reduction of 15% was observed (P ¼ 0.221). The maxi-
mum difference, 26% (P ¼ 0.064) between emapticap and pla-
cebo, was seen 8 weeks after discontinuation of treatment. At
Week 12, the HbA1c changed by0.31% in the emapticap ver-
sus þ0.05% in the placebo group (P ¼ 0.146). The maximum
difference for HbA1c was observed 4 weeks after the last dose
with 0.35% for emapticap versus þ0.12% for placebo (P ¼
0.026). No relevant change in blood pressure or estimated glo-
merular filtration rate was seen between the treatment groups
throughout the study. A post hoc analysis with exclusion of
patients with major protocol violations, dual RAS blockade or
haematuria increased the ACR difference between the two treat-
ment arms to 32% at Week 12 (P¼ 0.014) and 39% at Week 20
(P¼ 0.010).
Conclusions: Inhibition of the CCL2/CCL2 receptor axis with
emapticap pegol was generally safe and well tolerated. Beneficial
effects on ACR and HbA1c were observed in this exploratory
study, which were maintained after cessation of treatment.
Taken together, emapticap may have disease-modifying effects
that warrant further investigation in adequately powered confir-
matory studies.
Keywords: albuminuria, diabetes mellitus, diabetic nephrop-
athy, inflammation, macrophage
INTRODUCTION
Type 2 diabetes remains the leading cause (>40%) of new
patients requiring dialysis [1]. Diabetic nephropathy (DN)
develops over many years and is characterized by the gradual
increase in albuminuria and decline in renal function. The renal
and the cardiovascular risk of DN patients can be reduced with
angiotensin-converting enzyme inhibitors (ACEis) or angioten-
sin receptor blockers (ARBs), and the protective effect of these
drugs has at least partly been attributed to their albuminuria-
lowering effect [2]. However, there is a great need for novel
treatment modalities because the residual renal and cardiovas-
cular risk of this patient population remains high. It has been
demonstrated that interstitial macrophage infiltrates are com-
mon in DN [3] and in patients and animals, the pro-
inflammatory chemokine C-C motif-ligand 2 (CCL2), also
called monocyte-chemotactic protein 1 (MCP-1), is implicated
in the development of insulin resistance [4], as well as macro-
phage infiltration [3]. The role of macrophages in inflammation
and even proteinuria has been underscored in diabetic mouse
models [5, 6]. More recently, it was shown that urinary CCL2
levels are elevated in women before clinical findings of DN,||
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underlying the potential importance of inflammatory processes
in the pathophysiology of the disease [7, 8]. A CCL2 antagoniz-
ing L-RNA aptamer (Spiegelmer) reduced glomerular macro-
phages by 40%, improved diffuse glomerulosclerosis and
inhibited decline in glomerular filtration rate in uninephrec-
tomized db/db mice [9]. Blocking the CCL2 receptor CCR2
with other compounds produced similar results in the db/db
model [10–13]. These data have substantiated the hypothesis
that blockade of the CCL2/CCR2 axis might be a meaningful
new therapeutic target to treat patients with diabetic kidney
injury [14, 15]. Emapticap pegol (NOX-E36) is a 40-nucleotide
oligonucleotide aptamer that binds and inhibits CCL2 with
high affinity and specificity. Emapticap neither hybridizes with
native nucleic acids nor activates the innate immune response
and was well tolerated in Phase I human trials [16, 17]. We
report the results of an exploratory Phase IIa study in diabetic
patients with albuminuria.
MATERIALS AND METHODS
This exploratory trial was conducted as a double-blind,
randomized multi-centre study in five European countries.
Seventy-six patients with DN were included with a 2:1 random-
ization to emapticap or placebo (Figure 1). The primary objec-
tive was to characterize the effect of emapticap on the change in
urinary albumin/creatinine ratio (ACR). Secondary objectives
included evaluation of the effect on glycaemic control as well as
safety and tolerability. The study protocol was in accordance
with the Declaration of Helsinki (2002) and was approved by
local and central review boards (ClinicalTrials.gov Identifier:
NCT01547897). The main eligibility criterion was type 2 diabe-
tes according to American Diabetes Association definition with
an HbA1c from 6.0 to 10.5%. Patients had received stable anti-
diabetic, anti-hypertensive and lipid-lowering medication for 3
months prior to screening, including therapy with an ACEi
and/or an ARB. They had an ACR >100 mg/g in at least two
out of three morning void urines and an estimated glomerular
filtration rate (eGFR) >25 mL/min/1.73 m2 according to the
Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) formula. The major exclusion criteria were uncontrolled
hypertension (>180/110 mmHg), a cardiovascular event or
acute kidney injury in the last 3 months as well as treatment
with aliskiren, two or more diuretic drugs, systemic non-
steroidal anti-inflammatory drugs or thiazolidinediones.
Emapticap was administered subcutaneously at 0.5 mg/kg
twice weekly for 85 days, followed by a treatment-free observa-
tion period of 12 weeks (Figure 2). During the treatment phase,
ACR was determined as single measurements weekly or every
other week and during the follow-up every 4 weeks until Day
169, i.e. 12 weeks after treatment cessation. Urine samples for
ACR determination were shipped at ambient temperature to
the central lab and were analysed upon arrival using an immu-
noturbidimetric assay (Roche Modular). HbA1c was measured
every 4 weeks until Day 113, i.e. 4 weeks after treatment cessa-
tion. The complete clinical chemistry was measured in a central
laboratory (BARC, Belgium). Emapticap levels were measured
by NOXXON Pharma AG, Berlin, Germany.
Statistical analysis
This study was designed as an exploratory proof of concept
study and no formal sample size calculation was performed
prior to the start of the study. The primary objective was to
characterize the effect of study drug on the change in ACR
(Week 12 minus baseline) and this was compared with placebo
by analysis of covariance (ANCOVA) using baseline values as
covariate. As the parameter ACR is not normally distributed, a
logarithmic transformation was used to calculate mean changes
FIGURE 1: Consolidated Standards of Reporting Trials (CONSORT) diagram: summary of the disposition of study participants in the ITT
population and a post hoc analysis excluding patients with major protocol violations, dual RAS blockade or haematuria and leukocyturia.
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from baseline and respective 95% confidence intervals (CI).
These were back-transformed to provide geometric means with
respective 95% CI. Descriptive statistics are provided for all con-
tinuous study variables and categorical data are described by
absolute and relative frequencies. All statistical analyses were
performed using SASVR software version 9.1.3 or later (SAS
Institute, Cary, NC, USA). Independent statisticians performed
the interim analyses. During a treatment period of 4 weeks,
interim data from 12 patients were reviewed in a blinded fash-
ion in order to confirm the predicted pharmacokinetic/pharma-
codynamic profile (e.g. flow cytometry of monocytes) of the
study drug. After completion of the treatment phase of 27 and
51 patients, a pre-specified interim analysis for the efficacy
parameters and eGFR was performed.
Safety was assessed for all 76 patients who received at least
one dose of study medication. For the intent-to-treat (ITT)
analysis, the data from all 75 patients for whom both baseline
data and data on the primary efficacy variable for at least one
post baseline visit were available were analysed. For the assess-
ment of albuminuria, we also performed a post hoc analysis. For
this analysis, we excluded patients with major protocol viola-
tions, treatment with dual RAS blockade or haematuria and leu-
kocyturia (Figure 1) from the ITT population.
Statistical analyses were performed by the clinical research
organization (CRO) with validation by a biostatistician-advisor
of the sponsor. The authors had complete control over the
analysis.
RESULTS
Pharmacokinetics and pharmacodynamics
Recruitment began in March 2012, the first patient entered
the study in June 2012 and the study was completed in
December 2013. The baseline characteristics for the ITT popu-
lation are summarized in Table 1. The treatment duration was
12 weeks. After 2 weeks of treatment, steady-state plasma con-
centrations within the therapeutic range of 3556 105 nM were
reached (Supplementary data, Figure S1). The blood monocyte
count was reduced by 15–20% within 1 week after treatment
was commenced and remained lower than in the control group
throughout the study period (Figure 3A). Four weeks after stop-
ping treatment, this difference was markedly reduced; in addi-
tion, the density of the CCL2 receptor CCR2 on the surface of
the monocytes was 4- to 5-fold reduced (Figure 3B).
Albuminuria
At baseline, we observed a non-significant imbalance in the
urinary ACR between the two treatment groups (Table 1).
Treatment with emapticap lowered the ACR significantly by
29% (P < 0.05) at Day 85 versus baseline (Figure 4A). In the
placebo group, the ACR decreased non-significantly by 16%.
Compared with placebo, there was a trend towards reduction of
ACR by 15% (95% CI: 10.8 to 35.5%; P ¼ 0.221) in an
ANCOVA analysis. The time course of ACR during and after
treatment with emapticap is illustrated in Figure 4B. During the
first 2 months of treatment, both placebo and emapticap groups
showed a parallel decrease from baseline, whereas a separation
became apparent after Day 57. The therapeutic effect of emapti-
cap was maintained after the cessation of dosing until the end of
the 3-month treatment-free observation period (Figure 4B and
C). The maximum effect on mean ACR, a 40% reduction versus
baseline (P < 0.001) and a 26% reduction versus placebo (P ¼
0.064), were observed 4 and 8 weeks after the last dose, respec-
tively. RAS blockade and diuretic treatment remained stable
during the study period.
FIGURE 2: Study design.
FIGURE 3: (A) Time course of monocyte count change from base-
line (ANCOVA; ari-LS-means with 95% CI). (B) Flow cytometry of
exemplary patient pre-dose (Day 1) and after 4 weeks of dosing (Day
29).
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|Double RAS blockade and nephritic syndrome, i.e. the pres-
ence of haematuria and leukocyturia in addition to albuminuria,
are known to be confounding factors of ACR. Therefore, 12
patients who had received an ACEi and an ARB, and 5 patients
who had presented with nephritic syndrome at baseline were
excluded for a post hoc analysis, in addition to those with major
protocol violations. In fact, the baseline difference in ACR
between the placebo and emapticap group was markedly
reduced from 1.64-fold in the ITT population to 1.17-fold in
this post hoc analysis set of 49 patients (Supplementary data,
Table S1). In this subgroup of patients, emapticap treatment
reduced ACR by 30% (P < 0.05) versus baseline and 32% (P ¼
0.011) versus placebo at Day 85 (Figure 4D). An ACR reduction
of 50% was observed in 31% versus 6% (P ¼ 0.058)
(Supplementary data, Figure S2). Eight weeks after treatment
had been stopped, we observed a relative ACR reduction of 39%
(95% CI: 11.4 to 57.3%; P ¼ 0.010) in comparison with the
placebo arm (Figure 4E and F).
When comparing the ITT and post hoc analysis data, it is
obvious that (i) qualitatively, both sets show a virtually identical
time course of ACR—the specific beneficial effect sets in 2
months after start of treatment, improves further until end of
treatment and is maintained after cessation of dosing; (ii) quan-
titatively, the placebo-corrected effect of emapticap on ACR is
most pronounced and statistically significant in the post hoc
analysis, and maintained at least as a clear trend in the ITT pop-
ulation; and (iii) the improved separation in ACR between
emapticap and placebo in the post hoc analysis is mainly due to
reduced background noise in the placebo group.
No relevant difference in systolic or diastolic blood pressure
(Figure 5A) was seen between the treatment groups throughout
the study. In the emapticap group, the mean systolic and dia-
stolic blood pressure had changed by 1.5 and 0.4 mmHg at
Day 85 and in the placebo group by 3.6 and þ0.5 mmHg,
respectively. We observed a small comparable eGFR drop in
both groups of1.5 and2.2 mL/min at Day 85 for emapticap
and placebo, respectively (Figure 5B).
HbA1c
HbA1c levels were significantly reduced versus baseline lev-
els by 0.31% (P ¼ 0.014) in the emapticap group and non-
significantly in the placebo group (0.05%; P ¼ 0.843;
Figure 6A). The difference between the two groups showed a
trend towards improvement (P ¼ 0.146). The time course of
absolute change in HbA1c during and after dosing is illustrated
in Figure 6A. Emapticap showed a sustained steady decrease
from Day 1 to Day 85, whereas placebo revealed a slight initial
decrease to Day 57 with subsequent re-increase to baseline.
Four weeks after the last dose (Figure 6), we found a significant
difference between the two treatment arms (0.35 versus
þ0.12%; P ¼ 0.026). The concomitant change in HbA1c (on a
log scale) had no significant effect on the ACR change from
baseline (P¼ 0.3142).
Safety
Emapticap pegol was generally safe and well tolerated. No
treatment-related serious adverse event (AE) occurred during
the treatment and the follow-up phase. Three patients stopped
treatment prematurely because of AEs: two with treatment-
related skin reactions and one patient with urinary ACR
increase thought to be unrelated to treatment. In Table 2, all
AEs are listed. Most AEs were mild. The only relevant
treatment-related AEs were generally mild local injection site
reactions, which occurred in 18 and 4% of patients treated with
emapticap or placebo, respectively. The number of AEs of
severe intensity was balanced between emapticap and placebo,
and was of the type commonly observed in this population.
Cardiac disorders [unstable angina (n ¼ 1), atrioventricular
block first degree (n ¼ 1) and ventricular extrasystoles (n ¼ 1)]
and nervous system disorders [dizziness (n ¼ 2), disturbance in
Table 1. Patient characteristics at baseline for the ITT population
Emapticap (N ¼ 50) Placebo (N¼ 25) P-value t-testd
Male gender, n (%) 39 (78) 18 (72) 0.578e
Age (years)a 61.5 (5.7) 61.0 (8.4) 0.761
Body weight (kg)a 94.9 (17.8) 105.8 (26.4) 0.038
BMI (kg/m2)a 33.2 (6.1) 35.9 (6.7) 0.090
Duration of diabetes (years)a 12.4 (5.7) 14.5 (7.5) 0.177
Fasting plasma glucose (mg/dL)b 165 (152.5–178.8) 211 (186.0–238.3) 0.001
HbA1c (%)b 7.9 (7.58–8.19) 8.1 (7.68–8.53) 0.404
Supine blood pressure (mmHg)b
Systolic 142 (138.2–146.4) 142 (136.9–148.1) 0.963
Diastolic 79 (77.0–80.9) 78 (74.8–80.2) 0.373
Urinary ACR (mg/g)b 589 (428–809) 968 (551–1701) 0.096
Urinary ACR (mg/g)c 531 (244–1432) 834 (311–2385) 0.096
Serum creatinine (mmol/L)b 101.0 (94.2–108.5) 96.8 (84.2–111.2) 0.540
eGFR CKD-EPI (mL/min/1.73 m2)b 64 (58.2–70.7) 65 (55.1–77.3) 0.844
RAS blockade, n (%) 49 (98) 25 (100) –
ACEi only 21 (42) 17 (68)
ARB only 18 (36) 6 (24)
ACEi þ ARB 10 (20) 2 (8)
aArithmetic mean (SD).
bGeometric mean (95% CI).
cMedian (Q1 to Q3).
dBased on log values for geometric means.
eFisher’s exact test.
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|attention (n¼ 1) and headache (n¼ 1)] were observed sporadi-
cally and only in patients treated with emapticap. Taking into
account the small sample size and the fact that twice as many
patients were treated with emapticap, this asymmetric distribu-
tion is considered to be incidental, typical for the underlying
disease and not treatment related. The abnormal clinical labora-
tory tests (increases and decreases in haematology, coagulation
and clinical chemistry tests) reflected common findings in the
type 2 diabetic population without a specific direction and rele-
vant differences between treatment groups. ECG, vital signs and
physical examination showed changes also typical for the popu-
lation under study. No relevant difference in systolic or diastolic
blood pressure was seen between the treatment groups through-
out the study. At Day 85, the mean systolic/diastolic blood pres-
sure had changed by 1.8/0.2 mmHg and by 2.2/1.1 mmHg
for emapticap and placebo, respectively. No relevant change of
body weight occurred during the study.
DISCUSSION
Twelve weeks of treatment with 0.5 mg/kg emapticap was gen-
erally safe and well tolerated in patients with DN. There was a
trend towards reduced urinary albumin excretion and HbA1c.
FIGURE 4: Change in urinary ACR in the ITT population (A–C) and the post hoc analysis set (D–F). (A and D) Relative ACR change from
baseline versus placebo at end of treatment (ANCOVA; geo-LS-means and geo-LS-mean ratio with 95% CI); (B and E) absolute ACR time
course for emapticap and placebo during and after treatment; (C and F) relative change from baseline versus placebo (ANCOVA; geo-LS-mean
ratio with 95% CI).
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Four features of this treatment response were particularly intri-
guing: (i) that more than 2 months of treatment was required
before the beneficial effects became detectable versus placebo;
(ii) the maintenance of the effect on ACR after treatment cessa-
tion; (iii) the independence of the effect on ACR from relevant
blood pressure or eGFR changes; and (iv) the combination of
potential renoprotective and anti-diabetic activity. Such a pro-
file is clearly different from other agents known to decrease
albuminuria such as RAS blockers or endothelin receptor antag-
onists, which are characterized by a more rapid effect on protei-
nuria, blood pressure lowering and an abrupt return to baseline
after discontinuation [18–20]. We believe that the common
denominator for emapticap’s response profile is an anti-
inflammatory mode of action. Our data suggest that emapticap
reduces the amount of circulating monocytes. This is in agree-
ment with a previous animal study which showed that a CCL2
antagonizing Spiegelmer reduces the peripheral monocyte
count by inhibiting the CCR2-positive monocyte emigration
from the bone marrow to the blood [21]. Additionally, we
observed a reduction of the CCR2 density on the surface of the
monocytes. These two alterations should disable the monocytes
from accumulating in organ tissue and might explain the effects
observed in our study.
Recently, the role of monocyte/macrophage infiltration in
the pathogenesis of diabetic organ complications has been of
increasing interest [3]. Several animal studies and indirect evi-
dence from human studies have suggested that the inflamma-
tion associated with macrophage influx is critical for the
development of progressive kidney injury [3]. Furthermore,
mouse studies have indicated that the CCL2/CCR2 signalling
cascade is critical and blockade of this axis by different
approaches was able to improve proteinuria as well as progres-
sion of renal damage [9–13]. Monocytes contribute to glomeru-
lar damage and may induce matrix deposition and induction of
fibrosis. The present study suggests that these very promising
results in animal models translate well into human DN. At end
of 3 months of treatment, we observed a 29% reduction of albu-
minuria from baseline and 15% versus placebo, whereas the
maximum effect of 40% versus baseline and 26% versus placebo
FIGURE 6: Change in HbA1c in the ITT population. (A) Absolute
HbA1c time course for emapticap and placebo during and after treat-
ment. (B) Relative HbA1c change from baseline versus placebo
(ANCOVA, geo-LS-mean ratio with 95% CI).
FIGURE 5: Change in systolic and diastolic blood pressure (A) and
eGFR (B) in the ITT population. ||
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was found 4–8 weeks after cessation of treatment. Taking the
short treatment duration into account this result compares
favourably with other approaches like aliskiren and paricalcitol,
which showed 20 and 18% reduction on top of RAS blockade
after 6 months of treatment, respectively. The currently most
progressed and efficacious approach, the endothelin antagonist
atrasentan, showed a comparable effect size on urinary ACR
from baseline (36.2% reduction for the 0.75 mg/day dose) after
3 months of treatment [19]. However, in contrast to most of the
drugs mentioned and all RAS inhibitors, emapticap’s effect on
urinary albumin excretion is not associated with changes of
blood pressure or eGFR. This is in line with the findings in a
study with CCX140-B that targets the CCL2 receptor where the
reported reduction of urinary ACR (16% versus placebo for the
5 mg dose and 10% for the 10mg dose) was independent of hae-
modynamic changes [22]. Administration of the other drug
classes led to a fast reduction of albuminuria within 2–4 weeks
[18–20, 23], a blood pressure drop [18–20, 23, 24] and a decline
of the eGFR [18–20, 24], suggesting that all of these drugs have
a significant effect on systemic and/or intrarenal haemodynam-
ics. The absence of any relevant changes of blood pressure/
eGFR and the maintenance of the effect on ACR for several
weeks after cessation of treatment are in line with emapticap’s
anti-inflammatory mode of action. These data suggest that
CCL2 blockade influences important functional or structural
pathophysiological mechanisms of DN, which differentiates
CCL2 blockade from the existing therapeutic strategies and
indicates the disease-modifying potential of this approach. A
meta-analysis of 21 trials with the aim to delineate the associa-
tion between changes in albuminuria and end-stage renal dis-
ease found an association of interventions that reduced
albuminuria by at least 15% during the first months of treat-
ment and improved hard renal outcomes [25]. The observed
magnitude of the ACR reduction on top of standard of care
therefore suggests that emapticap has renoprotective potential.
Recent studies in mice have suggested uniformly that block-
ade of the CCL2 receptor CCR2 will lead to an improvement of
insulin resistance and glycaemic control [11–13]. The data
obtained in the current study suggest that blockade of CCL2 is
indeed able to improve hyperglycaemia in patients with type 2
diabetes. The notable reduction of absolute HbA1c levels after 3
months of treatment by 0.3–0.4% on top of standard diabetes
drugs may be attributed to changes in the inflammatory milieu
of the pancreatic islet cells and/or the adipose tissue. We cannot
exclude that the positive effect on HbA1c might have contrib-
uted partially to the effect on albuminuria. In the ACCORD
study, an HbA1c reduction of 1.3% in the intensive treatment
arm was accompanied by 12.5% lower urinary ACR levels in
comparison to the standard glycaemia control arm [26].
However, Levin et al. [27] observed no effect on urinary ACR
levels after 1-year intensive glycaemic control in type 2 diabetic
patients with microalbuminuria. We did not observe a signifi-
cant effect of the HbA1c changes on the degree of albuminuria.
In contrast, the anti-inflammatory drug salicylate (salsalate)
also reduced HbA1c in type 2 diabetic patients by a similar
degree of 0.37%, but increased albuminuria [28], suggesting
that the mode of action on the inflammatory milieu is different
between the two treatment strategies.
We are aware that this exploratory study has limitations.
First, the influence of confounding factors on the volatile
parameter urinary ACR can be expected to be substantial. One
of these confounding factors is dual RAS blockade, which had
been received by 16% of the patients in the study. Dual RAS
blockade reduces albuminuria to a greater extent than single
RAS blockade [29], but has been linked to worse renal outcome
[30] even in macroalbuminuric patients [31, 32]. As a conse-
quence, dual blockade has been removed from the 2013 pub-
lished European Society of Hypertension guidelines and is now
even labelled as contraindicated [33]. Another confounding fac-
tor of the ACR is nephritic syndrome, i.e. the triad of albuminu-
ria, haematuria and leukocyturia, which indicate the presence of
an additional, more acute inflammatory status [34, 35]. In an
attempt to exclude these confounders, we performed a post hoc
analysis of the per-protocol set without patients on dual RAS
blockade and patients with nephritic syndrome, and in fact the
change in ACR became significant versus placebo in this patient
Table 2. Summary of AEs
Adverse event Emapticap (N ¼ 51), % Placebo (N ¼ 25), % Total (N ¼ 76), %
Any adverse event 51 36 46
Any serious adverse event (e.g. humerus fracture, erysipela, unstable angina,
hypertension, diabetic foot, appendicitis)
10 8 9
Infections 18 20 18
General disorders and administration site disorders
(e.g. hematoma, pain, erythema, oedema)
18 8 15
Musculoskeletal and connective tissue disorders 10 12 11
Gastrointestinal disorders 8 8 8
Injury, poisoning and procedural complications 6 12 8
Metabolism and nutrition disorders 8 4 7
Investigations (clinical laboratory tests) 6 4 5
Vascular disorders 6 4 5
Cardiac disorders 6 0 4
Nervous system disorders 6 0 4
Skin and subcutaneous tissue disorders 4 4 4
Respiratory, thoracic and mediastinal disorders 2 4 3
Blood and lymphatic system disorders 2 0 1
Eye disorders 0 4 1
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|subset. It is important to note that only the ACR time course in
the placebo group was markedly different in this subset com-
pared with the ITT population, whereas there was only minor
change in the emapticap group. This signal of a potential reno-
protective effect of emapticap remains to be verified in an
adequately powered study with concrete endpoints. Second,
although this was a randomized study, several baseline charac-
teristics were not balanced between the groups due to the small
sample size. This imbalance may have contributed to a worse
renal and metabolic outcome in the placebo group, which had
significantly higher plasma glucose level and non-significantly
higher urinary ACR and HbA1c at baseline as well as higher
body mass index and longer duration of diabetes.
Our results suggest an important role of CCL2 and inflam-
matory mechanisms in the pathogenesis of DN. Emapticap is a
novel approach with potential for treating DN. As the need is
great and the therapeutic options are limited, we suggest that
the utility of emapticap should be assessed in larger trials.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford-
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ABSTRACT
Background: Until today, research has underestimated the role
of psychosocial conditions as contributing factors to dialysis
modality choice. The novelty within the Choice of Renal
Replacement Therapy (CORETH) project (German Clinical
Trials Register #DRKS00006350) is its focus on the multivariate
associations between these aspects and their consecutive signifi-
cance regarding treatment satisfaction (TS) in peritoneal dialysis
(PD) versus haemodialysis (HD) patients. In this article, we
present the baseline results of a multicentre study, which is sup-
ported by a grant from the German Ministry for Education and
Research.
Methods: Six to 24 months after initiation of dialysis, 780
patients from 55 dialysis centres all over Germany were sur-
veyed. The questionnaire addressed psychosocial, physical,
socio-demographic and shared decision-making (SDM) aspects.
Furthermore, cognitive functioning was tested. After indexing
the measures, two propensity score-matched groups (n ¼ 482)
were compared in a first step, after having chosen PD or HD. In
a second step, a moderated multiple regression (n ¼ 445) was
conducted to initially investigate the multivariate impact of
patient characteristics on TS.
Results: In comparison with HD patients, PD patients were
more satisfied with their treatment (P < 0.001), had a more
autonomy-seeking personality (P ¼ 0.04), had better cognitive
functioning (P ¼ 0.001), indicated more satisfying SDM (P <
0.001) and had a larger living space (P < 0.001). All patients
were more satisfied when they had a good psychological state
and received SDM. Especially in HD patients, TS was higher
when the patient had a less autonomous personality, lower cog-
nitive functioning, more social support, a poorer physical state
and poorer socio-demographic conditions (R2¼ 0.26).
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